Korean J Urol Oncol.  2021 Feb;19(1):30-39. 10.22465/kjuo.2021.19.1.30.

The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment

Affiliations
  • 1Department of Urology, Chung-Ang University College of Medicine, Seoul, Korea

Abstract

Urothelial cancer is the seventh most common cancer among men worldwide. Bacille de Calmette-Guérin is a type of anticancer immunotherapy that has been used to treat targeted bladder cancer, but the number of patients with treatment-refractory advanced urothelial cancer, patients has been increasing recently. To overcome this, enfortumab vedotin (novel nectin-4 targeting antibody-drug conjugate) known as antibody-drug conjugate (ADC), was approved. We describe the clinical development process of ADC and the potential for future development as a bladder cancer treatment.

Keyword

Antibody-drug conjugateㆍHER2ㆍImmunotherapyㆍNectin-4ㆍUrothelial carcinoma
Full Text Links
  • KJUO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error